Bounded definition
The cited phase 1 report describes systemic administration, dose cohorts, biomarker response, and early safety observations for a liver-targeted CRISPR intervention. Within this page, that proposition is limited to The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
Definition and evidence boundary
A process that administers editor components directly so that delivery, editing, and biological response occur inside the participant or organism. The bounded proposition retained by the canonical record is: The cited phase 1 report describes systemic administration, dose cohorts, biomarker response, and early safety observations for a liver-targeted CRISPR intervention.
The applicable scope is The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. This definition must not be generalized beyond the cited source and exact record boundary.
Claims: urn:maha:claim:in-vivo-genome-editing-workflow
Mechanism and technical context
The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis. This is the source-bound technical context for the record; no uncited mechanism is added by the compiler.
Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target. The mechanism or method is therefore presented as one component of a larger system, not as evidence for every downstream outcome.
Claims: urn:maha:claim:in-vivo-genome-editing-workflow
How to interpret the evidence
There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices. The evidence maturity recorded here is single study, and the claim kind is empirical claim.
This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded. Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets. These qualifications travel with the claim whenever it is reused.
Claims: urn:maha:claim:in-vivo-genome-editing-workflow
What the source supports and what remains unknown
The inspected source supports exactly this: The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis. It was read at Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.
What remains unknown is everything outside that locator. Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target. No quantity, comparison, or downstream outcome is established here unless a separately scoped record measures it.
Claims: urn:maha:claim:in-vivo-genome-editing-workflow
Source identity, locator, and reuse boundary
The bound source is “CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis” by Julian D. Gillmore, Ed Gane, Julian Taubel, Jingzhu Kao, et al., published by The New England Journal of Medicine on 2021-06-26; its declared stable identity is doi:10.1056/NEJMoa2107454.
The inspected-content locator is Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis. Reuse is limited to citation-with-paraphrase. Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced. This metadata establishes source identity and inspection scope, not the truth of claims outside the cited locator.
Claims: urn:maha:claim:in-vivo-genome-editing-workflow
Comparison and calculation boundary
Applicability is decided explicitly, not filled with generic material.
This record carries 1 source-bound proposition and therefore has no second supported side. A comparison would have to be manufactured from an adjacent title rather than from a second inspected claim, which the gate forbids.
The canonical claim declares no reproducible numerical inputs, equation, units, or uncertainty propagation; recorded uncertainty kind is qualitative. Supplying sample values would invent an unsupported quantitative result.
Limitations and prohibited inference
The claim stops where its evidence stops.
- record boundary
Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target.
- record boundary
A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record.
- prohibited inference
Do not treat the in-vivo genome-editing workflow record as medical advice, a treatment recommendation, or evidence of general clinical readiness.
- prohibited inference
Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract.
- editorial
This compilation reorganizes an existing inspected claim and its declared source; it does not add a new experiment, measurement, or independent replication.
- editorial
Internal editorial inspection is not external peer review, and no result on this page has been independently reproduced.
Related records and mathematical bridges
Typed links expose context without asserting equivalence.
Adenine base editing
Same canonical domain (synthetic-biology). Domain membership only: no shared source or declared edge links these two records.
Selection: domain adjacency
Genome-editor delivery systems
Declared mechanistic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.
Selection: bridge edge
In-vitro versus in-vivo evidence
Declared mechanistic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.
Selection: bridge edge
When no declared bridge edge is present, related records are linked by shared evidence or canonical domain adjacency. Those links are navigational and do not claim mathematical or physical equivalence.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
Genome-editor delivery systems
inbound connection · method
In-vivo editing depends on tissue exposure produced by a delivery system.
Genome-editor delivery systems
outbound connection · method
The in-vivo workflow depends on tissue-specific delivery and exposure.
In-vitro versus in-vivo evidence
outbound connection · comparison
In-vivo observations are a distinct evidence state from biochemical and cell-culture experiments.
In-vitro versus in-vivo evidence
inbound connection · comparison
The in-vivo workflow supplies one human intervention evidence state.
Claim ledger
Every proposition keeps its own evidence state.
The cited phase 1 report describes systemic administration, dose cohorts, biomarker response, and early safety observations for a liver-targeted CRISPR intervention.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
- Boundary
- Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · The New England Journal of Medicine
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore, Ed Gane, Julian Taubel, Jingzhu Kao, et al.
- Exact locator
- Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.
- Establishes
- The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.
- Boundary
- Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
- Declared interests
- The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed.